Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)
This study has been completed.
Study NCT00520390 Information provided by Enzon Pharmaceuticals, Inc.
First Received on August 23, 2007. Last Updated on April 1, 2010
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Advanced Solid Tumors
Additional conditions recognized in this trial
More general conditions related to this trial
Immune System Diseases
Neoplasms by Histologic Type
Interventions listed in this trial
Sponsors listed in this trial
Enzon Pharmaceuticals, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers